Company: MDCXW
Filing Date: 2025-05-27
Form Type: S-1
Source: 0001062993-25-010333
Chunk: 82

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-27
Form: S-1
Chunk 82
---
 subject to a number of conditions, including that the Company file a registration statement with the SEC registering the resale of the common shares issuable thereunder, and that the registration statement is declared effective by the SEC.

The total number of common shares issuable under the terms of the SEPA is limited to a number equivalent to 19.99% of the outstanding common shares, as of the date of the SEPA unless certain pricing conditions are met, which could have the effect of limiting the total proceeds made available to the Company under the SEPA. The issuance of common shares under the SEPA is subject to further limitations, including that the common shares beneficially owned by the Investor and its affiliates at any one time will not exceed 4.99% of the then-outstanding common shares.

Common shares issued and sold to the Investor under the SEPA will be priced at 97% of the market price (as defined in the SEPA) of the common shares during a specified three-day pricing period. The Company reserves the right to set a minimum acceptable price for the common share issuances.

|                                       |     |            |   |     | For the three months ended March 31, |   |
|                                       |     |       2025 
          $ |   |     |                                 2024 
                                    $ |   |
| Cash used in operating activities     |     | (3,940,994 | ) |     |                           (1,176,933 | ) |
| Cash provided by financing activities |     |  3,759,101 |   |     |                                    - |   |
| Net change in cash during the year    |     |   (181,893 | ) |     |                           (1,176,933 | ) |
| Cash, beginning of the year           |     |  4,164,323 |   |     |                            1,719,338 |   |
| Cash, end of the year                 |     |  3,982,430 |   |     |                              542,405 |   |

Cash flows used in operating activities

Cash flows used in operating activities for the three months ended March 31, 2025 were $3,940,994 compared to cash flows used in operating activities of $1,176,933 for the three months ended March 31, 2024. The increase is primarily due to increased spending on research and development activities for our SKNJCT-003 study and trials and increased general and administrative expenses